Literature DB >> 2677299

Killing of Cryptococcus neoformans by rat alveolar macrophages.

B Bolaños1, T G Mitchell.   

Abstract

The addition of [51Cr]-labeled yeast cells of Cryptococcus neoformans to monolayers of Lewis rat alveolar macrophages (AM phi) provided a sensitive and reproducible in vitro assay of phagocytosis. AM phi and yeast cells were incubated in 10% (v:v) normal rat serum for 1 h, non-AM phi associated yeast cells were removed and the AM phi-associated radioactivity (phagocytosis) determined. Replicate wells were replenished with fresh medium and reincubated. At different times, yeast-AM phi monolayers were treated with a non-cryptococcocidal mixture of DNAse and sodium deoxycholate to release the yeast cells from the AM phi. The fate of the yeast cells was critically evaluated by [51Cr]-release and viable plate counts. Killing was detected by plate counts within an hour following phagocytosis and did not increase significantly during the next 5 h. Strains of C. neoformans with small, medium, or large capsules varied in their susceptibility to killing from 10% to 95% but susceptibility to killing was not directly related to capsule size and the extent of phagocytosis. Release of 51Cr did not correlate with viability as determined by culture. The 51Cr was associated with two pools in the yeast cells; one, representing 15-20% of the radiolabel, was easily released and was probably bound to low molecular weight compounds in the cytoplasm. The majority of label was tightly bound to the particulate alkali-soluble cell wall fraction.

Entities:  

Mesh:

Year:  1989        PMID: 2677299

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  18 in total

Review 1.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

2.  Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection.

Authors:  Kirsten Nielsen; Gary M Cox; Anastasia P Litvintseva; Eleftherios Mylonakis; Stephanie D Malliaris; Daniel K Benjamin; Steven S Giles; Thomas G Mitchell; Arturo Casadevall; John R Perfect; Joseph Heitman
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Jatin M Vyas; Stuart M Levitz
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

5.  Intravascular granuloma induced by intravenous inoculation of Cryptococcus neoformans.

Authors:  H Yamaoka; N Sakaguchi; K Sano; M Ito
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

6.  Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components.

Authors:  Karen L Wozniak; Stuart M Levitz
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

7.  Differential activation of peritoneal cells by subcutaneous treatment of rats with cryptococcal antigens.

Authors:  José L Baronetti; Laura S Chiapello; Ana P Garro; Diana T Masih
Journal:  Clin Vaccine Immunol       Date:  2009-06-03

8.  Effect of endothelial cells on phagocyte-mediated anticryptococcal activity.

Authors:  S A Roseff; S M Levitz
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

9.  Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2).

Authors:  Oscar Zaragoza; Bettina C Fries; Arturo Casadevall
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans.

Authors:  C H Mody; G H Chen; C Jackson; J L Curtis; G B Toews
Journal:  Mycopathologia       Date:  1994-01       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.